Experimental Therapeutics of Anti-Cancer Agents with Phase I Emphasis

以 I 期为重点的抗癌药物实验治疗

基本信息

批准号：
8725825
负责人：
MICHAEL R GREVER
金额：
$ 85.23万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-03-28 至 2019-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8725825
关键词：
Antineoplastic Agents Basic Science Biological Assay Biological Markers Biomedical Research Blood Cancer Patient Cancer Therapy Evaluation Program Characteristics Clinical Clinical Investigator Clinical Research Clinical Trials Clinical Trials Design Clinical Trials Network Collaborations Commit Comprehensive Cancer Center Correlative Study Data Development Developmental Therapeutics Program Disease Disease Progression Dose Drug Administration Schedule Drug Kinetics Effectiveness Eligibility Determination Engineering Evaluation Exposure to Faculty Functional Imaging Functional disorder Future Genomics Goals Gynecologic Oncologist Hematologic Neoplasms Hematologist Hepatic Image Analysis Individual Investigation Investigational Drugs Joints Kidney Knowledge Laboratories Laboratory Study Lead Letters Malignant Neoplasms Medical Oncologist Medicine Mentors Minority Mission Molecular Target National Cancer Institute New Agents New Drug Approvals Ohio Outcome Patients Pharmaceutical Preparations Pharmacodynamics Pharmacogenomics Pharmacy facility Phase Phase I Clinical Trials Physicians Population Postdoctoral Fellow Principal Investigator Protocols documentation Public Health Nurses Public Health Nursing Radiation Oncologist Recommendation Regimen Relapse Research Research Design Research Personnel Research Project Grants Resistance Safety Schedule Scheme Science Scientist Signal Pathway Solid Neoplasm Specimen Supervision Surgical Oncologist Testing Therapeutic Therapeutic Agents Therapy Clinical Trials Time Toxic effect Universities Variant base career development clinical effect college design drug testing experience improved named group next generation novel novel therapeutics patient population patient safety programs response safety testing standard care tumor

项目摘要

DESCRIPTION (provided by applicant): This project encompasses a multi-disciplinary team of basic scientists and clinical investigators dedicated to finding effective new therapies for patiens with cancer. The Ohio State University Comprehensive Cancer Center is a truly comprehensive biomedical research campus with strong collaboration between the experienced investigators including faculty from the respective Colleges of Medicine, Pharmacy, Public Health, Nursing, and Engineering. Investigators in our Experimental Therapeutics Program have been engaged in phase l/ll cancer studies for decades. Our patient population supports robust accrual to NCI-sponsored early clinical trials. Each clinical trial engages a team of scientists with incorporatio of near real-time pharmacokinetics, pharmacodynamics, and pharmacogenomics correlative studies. We have collaborated extensively with other centers dedicated to experimental therapeutics. After defining the safety profile and clinical characteristics of novel agents, our investigators pursue the subsequent development of strategic combination regimens. While our data has been utilized in supporting new drug approvals by the FDA, we explore hypothesis-driven therapeutic trials. We do not simply test drugs. The future of molecular-targeted therapy, genomic profiling of a patient's tumor and the identification of relevant predictive biomarkers wil be explored in clinical studies designed with CTEP. In addition to vigorous pursuit of novel therapeutic agents, our multi-disciplinary team has been heavily engaged in educating the next generation of translational scientists dedicated to experimental therapeutics. Our junior faculty and post-doctoral trainees are provided with the opportunity to lead phase I clinical trials. Our principal investigators include medical oncologists, hematologists, radiation oncologists, gynecologic oncologists, and surgical oncologists. The emphasis is on mentoring allowing the junior investigators to chair the studies under experienced supervision. Basic scientists are invited to join each team in developing the letter of intent, designing the clinical trial, and the engaging in the scientific discovery of developmental therapy. Early clinical trials represent a longstanding emphasis of our research mission to improve patients' lives.

描述（由申请人提供）：该项目涵盖了一支由基础科学家和临床研究人员组成的多学科团队，致力于为患有癌症的patiens寻找有效的新疗法。俄亥俄州立大学综合癌症中心是一个真正综合的生物医学研究校园，在经验丰富的研究人员之间进行了强有力的合作，包括来自各自医学，药房，公共卫生，护理和工程学的教师。数十年来，我们的实验治疗计划中的研究人员已经从事L/LL癌症研究。我们的患者群体支持NCI赞助的早期临床试验的强大应计。每项临床试验都涉及一组科学家，并结合了近实时的药代动力学，药效学和药物基因组学相关研究。我们已经与致力于实验疗法的其他中心进行了广泛的合作。在定义了新型药物的安全性和临床特征之后，我们的研究人员追求了战略组合方案的随后发展。尽管我们的数据已用于支持FDA的新药物批准，但我们探讨了假设驱动的治疗试验。我们不仅要测试药物。分子靶向疗法的未来，患者肿瘤的基因组分析和相关预测生物标志物的鉴定，将在使用CTEP设计的临床研究中探索。除了对新颖的治疗剂的剧烈追求外，我们的多学科团队还大量参与教育下一代的转化科学家，致力于实验性治疗剂。我们的初级教师和博士后学员有机会领导I期临床试验。我们的主要研究人员包括医学肿瘤学家，血液学家，放射肿瘤学家，妇科肿瘤学家和外科肿瘤学家。重点是指导允许初级调查人员在经验丰富的监督下主持研究。邀请基础科学家加入每个团队，制定意向书，设计临床试验以及参与发展疗法的科学发现。早期的临床试验代表了我们的研究任务，以改善患者的生活。